Poster: Impact of Point-of-Sale Duplicate Therapy Safety Alert on Concomitant DPP-4 Inhibitor and GLP-1 Agonist Use
.jpg)
Key Findings
- Duplicate therapy point-of-sale edits can be an effective means of reducing the concomitant use of a GLP-1 agonist and DPP-4 inhibitor.
- It is important to implement safeguards at the point-of-sale to ensure that diabetes regimens are safe, clinically effective, and cost-conscious.
Capital Rx's Lauren Carroll, PharmD, BCACP (Manager, Clinical Programs), Angela Kalantarova, PharmD (Senior Manager, Clinical Programs), Brigitte Kinsey (Senior Manager, Clinical Analytics), Bonnie Hui-Callahan, PharmD, CDCES, (Senior Director, Clinical Programs), Jay Tran, PharmD, MHA(VP, Clinical Operations), and Sara Izadi, PharmD (Chief Clinical Officer) conducted a study seeking to measure the potential to reduce waste in for form of day supply overlap.
By implementing point-of-sale safety alerts on duplicate therapy for glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors through Judi®, our cloud-native enterprise health platform, we saw a meaningful reduction in the percentage of instances with day supply overlap.
The team presented their research findings at the Pharmacy Quality Alliance 2024 Annual Meeting. Review or download the poster below to see their findings.
Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.
